COHERUS BIOSCIENCES INC. - COMMON STOCK

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

08 5 2024 09:00:00 提供 Nasdaq GlobeNewswire

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

01 5 2024 16:30:00 提供 Nasdaq GlobeNewswire

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 4 2024 10:02:18 提供 Nasdaq GlobeNewswire

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

08 4 2024 08:30:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

13 3 2024 16:01:00 提供 Nasdaq GlobeNewswire

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

05 3 2024 16:01:00 提供 Nasdaq GlobeNewswire

Coherus Completes Divestiture of Ophthalmology Franchise

04 3 2024 01:00:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

23 2 2024 17:33:13 提供 Nasdaq GlobeNewswire

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

21 2 2024 08:30:00 提供 Nasdaq GlobeNewswire

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

05 2 2024 08:00:01 提供 Nasdaq GlobeNewswire

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

22 1 2024 01:15:00 提供 Nasdaq GlobeNewswire

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

18 1 2024 16:05:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 1 2024 09:00:00 提供 Nasdaq GlobeNewswire

Coherus Announces U.S. Launch of LOQTORZI™

02 1 2024 08:29:00 提供 Nasdaq GlobeNewswire

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

26 12 2023 16:01:00 提供 Nasdaq GlobeNewswire

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

11 12 2023 08:30:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences Announces CFO Transition Plans

07 12 2023 17:55:48 提供 Nasdaq GlobeNewswire

Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress

06 12 2023 04:00:00 提供 Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

28 11 2023 11:16:23 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

10 11 2023 09:49:53 提供 NetDania Notify